Xenetic Biosciences Reports FY Net Loss of $2.7 Million Amid Investment in Promising Programs

Xenetic Biosciences reported a net loss of $2.7 million for FY 2025, with increased royalty revenue from a sublicense with Takeda Pharmaceuticals. The company's focus on promising scientific programs contributed to the loss.